Jiangsu Fuxinyu Pharmaceutical Technology

Jiangsu Fuxinyu Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Changzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on high-selectivity kinase inhibitors for the treatment of autoimmune diseases, inflammatory conditions, and hematological malignancies. Its lead program, FX-108, is a potent and selective JAK1 inhibitor currently in Phase 2 clinical trials for indications such as atopic dermatitis and rheumatoid arthritis. Fuxinyu's pipeline also includes multi-target inhibitors like FX-101, which targets JAK2 and FLT3 for oncology applications. The company aims to provide more effective and safer therapeutic options for patients globally through its proprietary R&D capabilities. By leveraging its expertise in medicinal chemistry and kinase biology, Fuxinyu continues to expand its portfolio of candidates targeting unmet medical needs.